Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 2/2014

01-02-2014 | Breast Oncology

Androgen Receptor-Positive Triple Negative Breast Cancer: A Unique Breast Cancer Subtype

Authors: Lee J. McGhan, MBBCh, Ann E. McCullough, MD, Cheryl A. Protheroe, BA, Amylou C. Dueck, PhD, James J. Lee, PhD, Rafael Nunez-Nateras, MD, Erik P. Castle, MD, Richard J. Gray, MD, Nabil Wasif, MD, Matthew P. Goetz, MD, John R. Hawse, PhD, Travis J. Henry, PhD, Michael T. Barrett, PhD, Heather E. Cunliffe, PhD, Barbara A. Pockaj, MD

Published in: Annals of Surgical Oncology | Issue 2/2014

Login to get access

Abstract

Background

The significance of androgen receptor (AR) expression in triple-negative breast cancer (TNBC) is unclear, and published studies so far have been inconclusive.

Methods

A tissue microarray was constructed using tissue obtained from 119 patients with primary TNBC and stained for AR expression. Other tissue types obtained included recurrent TNBC, normal breast tissue, adjacent ductal carcinoma-in situ (DCIS), lymph node (LN) and distant metastases. Positive AR expression was defined as ≥10 % nuclear staining.

Results

Epithelial tissue was present and evaluable in 94 TNBC patients with a total of 177 tissue cores. AR expression in TNBC was 22 of 94 (23 %). AR expression was higher in normal breast tissue (88 %) and adjacent DCIS (73 % overall). All LN metastases from AR-positive TNBC patients were also AR positive; in addition, no AR-negative TNBC patient had AR-positive LNs. AR expression was associated with older patient age (63 vs. 57 years, respectively, p = 0.051) and LN metastases (p = 0.033). Locoregional recurrence and overall/disease-specific survival were similar between AR-positive and AR-negative patients, although AR-positive patients had more advanced disease. On multivariate analysis, the presence of LN metastases was associated with poorer recurrence-free survival in AR-positive patients (hazard ratio, 4.34) (p = 0.031).

Conclusions

The AR is expressed in normal breast tissue, and expression decreases with advancement to DCIS and invasive cancer. AR-positive TNBC was more common in older patients and had a higher propensity for LN metastases. AR-positive TNBC may represent a breast cancer subtype with unique features that may be amenable to treatment with alternative targeted therapies.
Literature
1.
2.
Cauley JA, Lucas FL, Kuller LH, Stone K, Browner W, Cummings SR. Elevated serum estradiol and testosterone concentrations are associated with a high risk for breast cancer. Study of Osteoporotic Fractures Research Group. Ann Intern Med. 1999;130(Pt 1):270–7.PubMedCrossRef
3.
Luo X, Shi YX, Li ZM, Jiang WQ. Expression and clinical significance of androgen receptor in triple negative breast cancer. Chin J Cancer. 2010;29:585–90.PubMedCrossRef
4.
Gucalp A, Traina TA. Triple-negative breast cancer: role of the androgen receptor. Cancer J. 2010;16:62–5.PubMedCrossRef
5.
Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med. 2010;363:1938–48.PubMedCrossRef
6.
Niemeier LA, Dabbs DJ, Beriwal S, Striebel JM, Bhargava R. Androgen receptor in breast cancer: expression in estrogen receptor-positive tumors and in estrogen receptor-negative tumors with apocrine differentiation. Mod Pathol. 2010;23:205–12.PubMedCrossRef
7.
Rakha EA, El-Sayed ME, Green AR, Lee AH, Robertson JF, Ellis IO. Prognostic markers in triple-negative breast cancer. Cancer. 2007 109(1):25–32.PubMedCrossRef
8.
He J, Peng R, Yuan Z, et al. Prognostic value of androgen receptor expression in operable triple-negative breast cancer: a retrospective analysis based on a tissue microarray. Med Oncol. 2012;29:406–10.PubMedCrossRef
9.
Park S, Koo J, Park HS, et al. Expression of androgen receptors in primary breast cancer. Ann Oncol. 2010;21:488–92.PubMedCrossRef
10.
11.
Ogawa Y, Hai E, Matsumoto K, et al. Androgen receptor expression in breast cancer: relationship with clinicopathological factors and biomarkers. Int J Clin Oncol. 2008;13:431–5.PubMedCrossRef
12.
Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, Pietenpol JA. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011;121:2750–67.PubMedCentralPubMedCrossRef
13.
14.
Veronesi U, Pizzocaro G. Breast cancer in women subsequent to cystic disease of the breast. Surg Gynecol Obstet. 1968;126:529–32.PubMed
15.
Wong YC, Xie B. The role of androgens in mammary carcinogenesis. Ital J Anat Embryol. 2001;106(Suppl 1):111–25.PubMed
16.
Hackenberg R, Schulz KD. Androgen receptor mediated growth control of breast cancer and endometrial cancer modulated by antiandrogen- and androgen-like steroids. Steroid Biochem Mol Biol. 1996;56–6:113–7.CrossRef
17.
Danforth KN, Eliassen AH, Tworoger SS, et al. The association of plasma androgen levels with breast, ovarian and endometrial cancer risk factors among postmenopausal women. Int J Cancer. 2010;126:199–207.PubMedCentralPubMedCrossRef
18.
Schneider BP, Winer EP, Foulkes WD, Garber J, Perou CM. Triple-negative breast cancer: risk factors to potential targets. Clin Cancer Res. 2008;14:8010–18.PubMedCrossRef
19.
Reis-Filho JS, Tutt ANJ. Triple negative tumours: a critical review. Histopathology. 2008;52:108–18.PubMedCrossRef
20.
Kanga SP, Martelb M, Harris LN. Triple negative breast cancer: current understanding of biology. Curr Opin Obstet Gynecol. 2008;20:40–6.CrossRef
21.
Podoa F, Buydensb LMC, Deganic H, et al. Triple-negative breast cancer: present challenges and new perspectives. Mol Oncol. 2010;4:2099–29.
22.
Bryan RM, Mercer RJ, Bennett RC, Rennie GC, Lie TH, Morgan FJ. Androgen receptors in breast cancer. Cancer. 1984;54:2436–40.PubMedCrossRef
23.
Gonzalez-Angulo AM, Stemke-Hale K, Palla SL, et al. Androgen receptor levels and association with PIK3CA mutations and prognosis in breast cancer. Clin Cancer Res. 2009;15:2472–8.PubMedCrossRef
24.
Parker RL, Huntsman DG, Lesack DW, Cupples JB, Grant DR, Akbari M, Gilks CB. Assessment of interlaboratory variation in the immunohistochemical determination of estrogen receptor status using a breast cancer tissue microarray. Am J Clin Pathol. 2002;117:723–8.PubMedCrossRef
25.
Park S, Koo JS, Kim MS, et al. Androgen receptor expression is significantly associated with better outcomes in estrogen receptor-positive breast cancers. Ann Oncol. 2011;22:1755–62.PubMedCrossRef
26.
Billar JA, Dueck AC, Stucky CH, et al. Triple-negative breast cancers: unique clinical presentations and outcomes. Ann Surg Oncol. 2010;17(Suppl. 3):384–90.PubMedCrossRef
27.
Collins LC, Cole KS, Marotti JD, et al. Androgen receptor expression in breast cancer in relation to molecular phenotype: results from the Nurses’ Health Study. Mod Pathol. 2011;24:924–31.PubMedCentralPubMedCrossRef
Metadata
Title
Androgen Receptor-Positive Triple Negative Breast Cancer: A Unique Breast Cancer Subtype
Authors
Lee J. McGhan, MBBCh
Ann E. McCullough, MD
Cheryl A. Protheroe, BA
Amylou C. Dueck, PhD
James J. Lee, PhD
Rafael Nunez-Nateras, MD
Erik P. Castle, MD
Richard J. Gray, MD
Nabil Wasif, MD
Matthew P. Goetz, MD
John R. Hawse, PhD
Travis J. Henry, PhD
Michael T. Barrett, PhD
Heather E. Cunliffe, PhD
Barbara A. Pockaj, MD
Publication date
01-02-2014
Publisher
Springer US
Published in
Annals of Surgical Oncology / Issue 2/2014
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-013-3260-7

Other articles of this Issue 2/2014

Annals of Surgical Oncology 2/2014 Go to the issue

Gastrointestinal Oncology

Comparisons of Sixth and Seventh Edition of the American Joint Cancer Committee Staging Systems for Esophageal Cancer

Gastrointestinal Oncology

Oncologic Safety of Pylorus-preserving Gastrectomy in the Aspect of Micrometastasis in Lymph Nodes at Stations 5 and 6

Breast Oncology

The Number of Lymph Nodes Dissected in Breast Cancer Patients Influences the Accuracy of Prognosis

Hepatobiliary Tumors

Intraoperative Visualization of Hepatocellular Carcinoma with Indocyanine Green: Revealing the Mechanisms behind the Glowing Tumor

Gynecologic Oncology

Progress in Survival Outcomes in Patients with Advanced Ovarian Cancer Treated by Neo-Adjuvant Platinum/Taxane-Based Chemotherapy and Late Interval Debulking Surgery

Gastrointestinal Oncology

Determinants of Response to Neoadjuvant Chemotherapy for Esophageal Cancer Using 18F-fluorodeoxiglucose Positron Emission Tomography (18F-FDG-PET)